HHS said it will no longer allocate doses of COVID-19 antibody drugs from Eli Lilly and Regeneron because they are no longer in short supply, according to the American Hospital Association.
Healthcare providers should now order the drugs directly from AmerisourceBergen, the sole distributor of the antibody drugs.
The drugs will still be free, HHS said, according to a Feb. 19 news release from the hospital association.
"HHS will continue to monitor all direct orders, and we retain the capacity to resume allocation of these and future therapies if needed," HHS said.
HHS last month launched an online treatment locator that tracks facilities that have received shipments of Eli Lilly and Regeneron's COVID-19 antibody drugs.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.